L Iyer

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
    L Iyer
    Department of Human Genetics, Cancer Research Center, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 65:576-82. 1999
  2. ncbi request reprint Inherited variations in drug-metabolizing enzymes: significance in clinical oncology
    L Iyer
    Department of Medicine and Committee on Clinical Pharmacology, The University of Chicago, Chicago, Illinois 60637, USA
    Mol Diagn 4:327-33. 1999
  3. ncbi request reprint UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    L Iyer
    Department of Medicine, The University of Chicago, IL, USA
    Pharmacogenomics J 2:43-7. 2002
  4. ncbi request reprint Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer
    R B Ewesuedo
    Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
    J Clin Oncol 19:2084-90. 2001
  5. ncbi request reprint Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan
    F Innocenti
    Committee on Clinical Pharmacology, The University of Chicago, Illinois 60637, USA
    Drug Metab Dispos 29:596-600. 2001
  6. ncbi request reprint Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7
    F Innocenti
    The University of Chicago, Department of Medicine, Chicago, IL 60637, USA
    Drug Metab Dispos 29:686-92. 2001

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
    L Iyer
    Department of Human Genetics, Cancer Research Center, University of Chicago, IL 60637, USA
    Clin Pharmacol Ther 65:576-82. 1999
    ..The presence of an additional TA repeat [(TA)7TAA] in the TATA sequence of UGT1A1 has been associated with Gilbert's syndrome...
  2. ncbi request reprint Inherited variations in drug-metabolizing enzymes: significance in clinical oncology
    L Iyer
    Department of Medicine and Committee on Clinical Pharmacology, The University of Chicago, Chicago, Illinois 60637, USA
    Mol Diagn 4:327-33. 1999
    ....
  3. ncbi request reprint UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    L Iyer
    Department of Medicine, The University of Chicago, IL, USA
    Pharmacogenomics J 2:43-7. 2002
    ..The results suggest that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity...
  4. ncbi request reprint Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer
    R B Ewesuedo
    Committee on Clinical Pharmacology, Section of Pediatric Hematology-Oncology, Department of Pediatrics, University of Chicago, IL 60637, USA
    J Clin Oncol 19:2084-90. 2001
    ..Further studies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted...
  5. ncbi request reprint Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan
    F Innocenti
    Committee on Clinical Pharmacology, The University of Chicago, Illinois 60637, USA
    Drug Metab Dispos 29:596-600. 2001
    ..A clinical trial at the University of Chicago is ongoing to demonstrate the predictive significance of UGT1A1 genotyping for irinotecan pharmacodynamics...
  6. ncbi request reprint Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7
    F Innocenti
    The University of Chicago, Department of Medicine, Chicago, IL 60637, USA
    Drug Metab Dispos 29:686-92. 2001
    ..The reported tyrosine to histidine polymorphism in UGT2B7 does not alter the formation rate of epirubicin glucuronide, and undiscovered genetic polymorphisms in UGT2B7 might change the metabolic fate of this important anticancer agent...